How early to take arms against a sea of troubles? The case for aggressive early therapy in Crohn's disease to prevent fibrotic intestinal strictures

Journal of Crohn's and Colitis

Volumn 7, Issue 11, 2013, Pages 923-927

  Govani, Shail M ^a   Stidham, Ryan W ^a   Higgins, Peter D R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Crohn's Disease; Fibrosis; Fibrostenotic disease; Strictures; Top down therapy

Indexed keywords

ADALIMUMAB; ANGIOTENSIN II; AZATHIOPRINE; CERTOLIZUMAB PEGOL; IMMUNOMODULATING AGENT; INFLIXIMAB; LEVOFLOXACIN; SOMATOMEDIN BINDING PROTEIN 1; STEROID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; BALLOON DILATATION; BIOLOGICAL THERAPY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE DURATION; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL FIBROSIS; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL;

CD; CROHN'S DISEASE; FIBROSIS; FIBROSTENOTIC DISEASE; STRICTURES; TOP-DOWN THERAPY;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; EARLY DIAGNOSIS; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL OBSTRUCTION; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RISK ASSESSMENT; SECONDARY PREVENTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84884812449     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.06.011     Document Type: Article

References (33)

1. Peyrin-Biroulet L., Harmsen W.S., Tremaine W.J., Zinsmeister A.R., Sandborn W.J., Loftus E.V. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol 2012, 107:1693-1701.
2. Gasche C., Schölmerich J., Brynskov J., D'Haens G., Hanauer S.B., Irvine E.J., et al. A simple classification of Crohn's disease: report of the working party for the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000, 6:8-15.
3. Cosnes J., Cattan S.P., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
4. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El Yafi F.A., Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001, 49:777-782.
5. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
6. Colombel J.-F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
7. Vasilopoulos S., Kugathasan S., Saeian K., Emmons J.E., Hogan W.J., Otterson M.F., et al. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am J Gastroenterol 2000, 95:2503.
8. Jones D.W., Finlayson S.R.G. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg 2010, 252:307-312.
9. Ferlitsch A., Reinisch W., Püspök A., Dejaco C., Schillinger M., Schöfl R., et al. Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures. Endoscopy 2006, 38:483.
10. Couckuyt H., Gevers A.M., Coremans G., Hiele M., Rutgeerts P. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut 1995, 36:577-580.
11. Thomas-Gibson S., Brooker J.C., Hayward C.M.M., Shah S.G., Williams C.B., Saunders B.P. Colonoscopic balloon dilation of Crohn's strictures. Eur J Gastroenterol Hepatol 2003, 15:485-488.
12. Mueller T., Rieder B., Bechtner G., Pfeiffer A. The response of Crohn's strictures to endoscopic balloon dilation. Aliment Pharmacol Ther 2010, 31:634-639.
13. Gustavsson A., Magnuson A., Blomberg B., Andersson M., Halfvarson J., Tysk C. Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease. Aliment Pharmacol Ther 2012, 36:151-158.
14. Johnson L.A., Luke A., Sauder K., Moons D.S., Horowitz J.C., Higgins P.D.R. Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "top-down" approach to intestinal fibrosis in mice. Inflamm Bowel Dis 2012, 18:460-471.
15. Schreiber S., Colombel J.-F., Bloomfield R., Nikolaus S., Scholmerich J., Panes J., et al. Increased response and remission rates in short duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J of Gastroenterol 2010, 105:1574-1582.
16. Schreiber S., Reinisch W., Colombel J.-F., Sandborn W.J., Hommes D.W., Li J., et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology 2007, 132:A147.
17. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
18. Rubin D.T., Uluscu O., Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 2012, 18:2225-2231.
19. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
20. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
21. Lichtenstein G.R., Yan S., Bala M., Blank M., Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
22. Bodger K., Kikuchi T., Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009, 30:265-274.
23. Lichtenstein G.R., Olson A., Travers S., Diamond R.H., Chen D.M., Pritchard M.L., et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006, 101:1030-1038.
24. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
25. Vasiliauskas E.A., Kam L.Y., Karp L.C., Gaiennie J., Yang H. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000, 47:487-496.
26. Abreu M.T., Taylor K.D., Lin Y.C., Hang T., Gaiennie J., Landers C.J., et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002, 123:679-688.
27. Mow W.S., Vasiliauskas E.A., Lin Y.-C., Fleshner P.R., Papadakis K.A., Taylor K.D., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126:414-424.
28. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M., et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009, 136:441-450.
29. Papamichael K., Archavlis E., Lariou C., Mantzaris G.J. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis 2012, 6:924-931.
30. Aguas M. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol 2012, 18:4391.
31. Rockey D.C. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol 2013, 11:224-225.
32. Rahal K., Schmiedlin-Ren P., Adler J., Dhanani M., Sultani V., Rittershaus A.C., et al. Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease. Inflamm Bowel Dis 2012, 18:613-623.
33. Brook N.R., Waller J.R., Bicknell G.R., Nicholson M.L. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 2005, 125:137-143.